A549-ASC-GFP Reporter Cells for NLRP1 studies
|A549-ASC-NLRP1 Cells||Unit size||Cat. code||Docs||Qty||Price|
Human NLRP1 lung reporter cells
3-7 x 10e6 cells
|A549-ASC Cells||Unit size||Cat. code||Docs||Qty||Price|
A549 human lung carcinoma - ASC-GFP reporter cells
3-7 x 10e6 cells
Activation of NLRP1 in A549-ASC-NLRP1 cells
Several pathways can trigger human NLRP1 inflammasome activation.
a) Cleavage of NLRP1 in its N-terminal domain by viral proteases including 3C (Enterovirus) and 3CL (Coronavirus).
b) ZAK-α-dependent NLRP1-phosphorylation in its N-terminal domain following UVB exposure.
c) Sensing of long viral dsRNA through the LRR and NACHT domains.
d) Pharmacological inhibition of the NLRP1-repressors DPP-8/-9 by Val-boroPro.
All these activators converge in driving proteasomal degradation of NLRP1 N-terminal domain and release of the C-terminal part that recruits ASC::GFP and Caspase-1 leading to the NLRP1 inflammasome assembly. This triggers the formation of ASC-GFP specks, the release of cytokines (eg IL-16 and IL-18) and pyroptotic cell death.
Real time observation of ASC-GFP speck formation in A549 ASC-NLRP1 cells.
Movie showing ASC-Speck formation in A549-ASC-NLRP1 cells, previously primed with TNF-α for 24 h, and following addition of the NLRP1 activator Val-boroPro according to the VDS datas. The movie is accelerated, and one second corresponds to a duration of 1 hour. Cells are imaged using an EVOS M7000 fluorescence microscope, equipped with an incubator at 37°C, at the frequency of one image (bright field and GFP channel) every 5 minutes and up to 20 hours.
InvivoGen also offers:
Study of ASC-dependent NLRP1 inflammasome activation
InvivoGen offers a human A549 lung carcinoma-derived cell line specifically designed for assessing ASC-dependent NLRP1 inflammasome activation and its control cell line:
— A549-ASC-NLRP1 cells
— A549-ASC (control) cells
- These cells feature an NF-κB-inducible ASC::GFP reporter gene. This allows the monitoring of ASC-dependent inflammasome activation by visualizing ASC speck formation using fluorescence microscopy.
- Additionally, A549-ASC-NLRP1 cells have been engineered to stably express the human NLRP1 inflammasome sensor. Its activation can be monitored in real-time by following the formation of fluorescent ASC specks and measuring pyroptotic cell death with the LDH assay.
The NLRP1 inflammasome has been shown to play an important role in sensing viral infections, and ribotoxic stress. Additionally, NLRP1 mutations have been associated with several inflammatory diseases with skin phenotype.
Upon induction of ASC::GFP with the NF-κB inducer TNF-α and stimulation with the NLRP1 activator Val-BoroPro (VbP) or transfected Poly (I:C), A549-ASC-NLRP1 cells display ASC specks, visible as fluorescent green dots, and undergo pyroptosis, readily measurable by the LDH assay. NLRP1 inflammasome assembly occurs in A549 cells expressing NLRP1 as they endogenously express the inflammasome-related proteins, ASC (apoptosis-associated speck-like protein containing a CARD domain), Caspase-1 and Gasdermin D .
A549-ASC cells not only serve as a control cell line for A549-ASC-NLRP1 cells, they also offer the possibility to monitor ASC-dependent inflammasome activation of NLRP3 after its transgenic expression.
- Stable expression of human NLRP1 (isoform 1) (see Figures)
- NF-kB-dependent expression of the ASC::GFP fusion protein (see Figures)
- Screening of NLRP1 inflammasome activating stimuli
- Real-time monitoring of ASC-dependent inflammasome assembly
- Rapid and visual screening of drugs targeting the NLRP1 inflammasome by fluorescence microscopy
1.Planès R. et al., 2022. Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung epithelial cells. Mol Cell. S1097-2765(22).
Expression of NLRP1 and ASC::GFP in A549-ASC-NLRP1 cells. Cells were either left untreated or incubated with the NF-κB-inducer, human TNF-α (4 ng/ml), overnight at 37°C. Cell lysates were analyzed by Western blot using anti‑hNLRP1 and anti-hASC antibodies, and an HRP conjugated secondary antibody. Actin was used as a loading control.
ASC::GFP inducible expression in A549-ASC-NLRP1 cells. 5 x 104 cells were incubated with or without 4 ng/ml hTNF-α overnight at 37°C in 5% CO2. The next day, GFP expression was measured using flow cytometry and compared to untreated cells.
Functional validation of Val-boroPro-induced NLRP1 inflammasome activation.
A549-ASC-NLRP1 and A549-ASC cells were cultured with 4 ng/ml human TNF-α overnight at 37°C, 5% C02. The following day, the cells were further incubated, or not, with 10 µM of the NLRP1 inducer Val-boroPro (VbP) for 24 hours. The ASC::GFP speck formation were monitored using fluorescence microscopy at 8 hours post-treatment with VbP. Scale bar: 50 µm (A). Pyroptosis was assessed using the lactate dehydrogenase (LDH) assay at 24h. Data is shown as percentage of cell death (mean ± SEM) (B).
Functional validation of Poly(I:C) HMW-induced NLRP1 inflammasome activation. A549-ASC-NLRP1 and A549-ASC cells were cultured with 4 ng/ml human TNF-α overnight at 37°C, 5% C02. The following day, the cells were further incubated, or not, with 0.5 µg/ml transfected Poly(I:C) HMW overnight. The ASC::GFP expression and ASC speck formation were monitored using fluorescence microscopy. Scale bar: 50 µm (A). Pyroptosis was assessed using the lactate dehydrogenase (LDH) assay. Data is shown as percentage of cell death (mean ± SEM) (B).
Growth Medium: DMEM, 4.5 g/l glucose, 2 mM L-glutamine, 25 mM HEPES, 10% (v/v) fetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin, 100 µg/ml Normocin™
Antibiotic resistance: Blasticidin
- The expression and induction of ASC::GFP and NLRP1 have been verified by Western blot, fluorescence microscopy, and flow cytometry.
- The stability of this cell line for 20 passages following thawing has been verified.
- A549-ASC-NLRP1 cells are guaranteed mycoplasma-free.
This product is covered by a Limited Use License (See Terms and Conditions).Back to the top
- 3-7 x 106 A549-ASC-NLRP1 cells in a cryovial or shipping flask
- 1 ml of Blasticidin (10 mg/ml)
- 1 ml of Normocin™ (50 mg/ml)
Shipped on dry ice (Europe, USA, Canada and some regions in Asia)Back to the top
A549 cells for inflammasome studies
A549-ASC-NLRP1 cells were engineered from the human A549 lung carcinoma epithelial cell line, which endogenously express proteins involved in the inflammasome signaling including ASC, caspase-1, and Gasdermin D/E. However, they are unable to mount inflammasome responses because of the lack of expression of some sensors/co-sensors, as verified in the control cell line A549-ASC. Notably, they lack expression of NLRP1 and NLRP3, two sensors that are strictly dependent on the ASC adaptor to bridge their interaction with pro-caspase-1 (in-house data) .
The ASC adaptor
ASC (apoptosis-associated speck-like protein containing a CARD domain, aka PYCARD) is a protein adaptor important in canonical inflammasome responses [2-3]. ASC's bipartite composition, consisting of one PYD (pyrin domain) and one CARD (caspase recruitment domain) domain, allows the recruitment of the CARD-containing pro-caspase-1 to canonical inflammasome sensors . In resting cells, ASC is present in a soluble and diffuse form, both in the cytoplasm and nucleus. Upon inflammasome activation, ASC molecules form a single large, micrometer-sized, ‘speck’ per cell, thus concentrating caspase-1 activation sites .
The NLRP1 sensor
NLRP1 (aka NALP1) was the first described inflammasome sensor of the Nod-Like Receptors (NLR) family . Among other NLR, NLRP1 exhibit a unique structure with a PYRIN, NACHT and LRR in its N-terminal domain followed by a FIIND (function-to-find domain) and a CARD domain in its C-terminal region. The FIIND domain autocleaves NLRP1 into two proteins that persist connected in a non-covalent manner and in close association with the dipeptidyl peptidases DPP-8/-9, thereby maintaining NLRP1 in an auto-inhibitory state [3,4]. It took two decades to uncover the activation mechanisms of human NLRP1. The actual model relies on a "functional degradation" pathway , in which danger signals trigger proteasomal degradation of the NLRP1 N-terminal domain leading to the release of the C-terminal CARD containing domain, the active form of NLRP1. Subsequently, the ASC adaptor is recruited inducing the assembly of the NLRP1 inflammasome through oligomerization with pro-capase-1 [1,4].
So far, four activators of the NLRP1 pathway have been reported [1,6-12]:
The firstly identified pathway relies on pharmacological inhibition of the cellular proteases DPP-8/-9 by Val-boroPro. While the small molecule Val‐boroPro (Talabostat) was known since 2003 to stimulate anti-cancer immune responses [13-14], only recent work has identified its mechanism of action through activation of the NLRP1 inflammasome [6-8]. However, the physiological settings that trigger NLRP1 activation through DPP-8/DPP-9 inhibition are currently unknown.
The second pathway suggests that NLRP1 is acting as a decoy receptor aiming to detect viral proteases activities. Indeed, enteroviral 3C proteases [9-10] and coronaviral 3CL proteases , which are essential for maturation of viral proteins, have been shown to cleave NLRP1 within its N-terminal domain. Cleavage creates an unstable neo-N terminus that is rapidly degraded by the proteasome pathway, leading to NLRP1 inflammasome activation. In the context of SARS-CoV-2 infection, NLRP1 activation by the viral 3CL protease (NSP5) has been linked to lung epithelial cell death and inflammatory cytokine release, suggesting an important role of NLRP1 in COVID-19 pathophysiology .
Recent work has identified a third pathway by demonstrating that NLRP1 senses long dsRNA generated in the context of viral infection by Semliki Forrest Virus (SFV) . Interestingly, this pathway can be mimicked by transfection of high molecular weight poly I:C. Mechanistically, it was found that long dsRNAs (>500 bp) bind directly to NLRP1 (NACHT-LRR domain). This interaction activates the ATPase, NACHT domain of NLRP1 leading to its activation following proteasome-dependent degradation of the N-terminal part of NLRP1 .
Lastly, Zhong’s team have discovered that human NLRP1 also senses the ultraviolet B (UVB)- and toxin-induced ribotoxic stress response (RSR). Mechanistically, RSR leads to the direct phosphorylation of NLRP1 N-terminal region by the MAP3K ZAK-α and the MAPK p38 hence driving NLRP1 destabilisation and inflammasome activation .
Additionally, NLRP1 polymorphism within human population is linked to several rare genetic diseases and autoimmune diseases such as Psoriasis, vitiligo or type-1 diabetes [1-5, 15] and thus is actually considered as an important therapeutic target.
1. Planès R. et al., 2022. Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung epithelial cells. Mol Cell. 2022 Jul 7;82(13):2385-2400.e9. doi: 10.1016/j.molcel.2022.04.033. Epub 2022 May 16. PMID: 35594856; PMCID: PMC9108100.
2. Mathur A. et al., 2017. Molecular mechanisms of inflammasome signaling. J Leukoc Biol. 2018 Feb;103(2):233-257. doi: 10.1189/jlb.3MR0617-250R. Epub 2017 Dec 29. PMID: 28855232.
3. Hoss F. et al., 2017. Assembly and regulation of ASC specks. Cell Mol Life Sci. 2017 Apr;74(7):1211-1229. doi: 10.1007/s00018-016-2396-6. Epub 2016 Oct 19. PMID: 27761594.
4. Taabazuing et al., 2020. The NLRP1 and CARD8 inflammasomes. Immunol Rev. 2020 Sep;297(1):13-25. doi: 10.1111/imr.12884. Epub 2020 Jun 19. PMID: 32558991; PMCID: PMC7483925.
5. Sandstrom et al., 2019. Functional degradation: A mechanism of NLRP1 inflammasome activation by diverse pathogen enzymes. Science. 2019 Apr 5;364(6435):eaau1330. doi: 10.1126/science.aau1330. Epub 2019 Mar 14. PMID: 30872533; PMCID: PMC6532986.
6. Okondo et al., 2017. DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis. Nat Chem Biol. 2017 Jan;13(1):46-53. doi: 10.1038/nchembio.2229. Epub 2016 Nov 7. PMID: 27820798; PMCID: PMC5477230.
7. Taabazuing et al., 2017. Pyroptosis and Apoptosis Pathways Engage in Bidirectional Crosstalk in Monocytes and Macrophages. Cell Chem Biol. 2017 Apr 20;24(4):507-514.e4. doi: 10.1016/j.chembiol.2017.03.009. Epub 2017 Apr 6. PMID: 28392147; PMCID: PMC5467448.
8. Zhong et al., 2018. Human DPP9 represses NLRP1 inflammasome and protects against autoinflammatory diseases via both peptidase activity and FIIND domain binding. J Biol Chem. 2018 Dec 7;293(49):18864-18878. doi: 10.1074/jbc.RA118.004350. Epub 2018 Oct 5. PMID: 30291141; PMCID: PMC6295727.Robinson et al., 2022.
9. Tsu et al., 2021. Diverse viral proteases activate the NLRP1 inflammasome. Elife. 2021 Jan 7;10:e60609. doi: 10.7554/eLife.60609. PMID: 33410748; PMCID: PMC7857732.
10. Robinson et al., 2020. Enteroviral 3C protease activates the human NLRP1 inflammasome in airway epithelia. Science. 2020 Dec 4;370(6521):eaay2002. doi: 10.1126/science.aay2002. Epub 2020 Oct 22. PMID: 33093214.
11. Bauernfried et al., 2022. Human NLRP1 is a sensor for double-stranded RNA. Science. 2021 Jan 29;371(6528):eabd0811. doi: 10.1126/science.abd0811. Epub 2020 Nov 26. PMID: 33243852.
12. Robinson et al., 2022. ZAKα-driven ribotoxic stress response activates the human NLRP1 inflammasome. Science. 2022 Jul 15;377(6603):328-335. doi: 10.1126/science.abl6324. Epub 2022 Jul 14. PMID: 35857590.
13. Walsh et al., 2003. Val-boroPro accelerates T cell priming via modulation of dendritic cell trafficking resulting in complete regression of established murine tumors. PLoS One. 2013;8(3):e58860. doi: 10.1371/journal.pone.0058860. Epub 2013 Mar 12. PMID: 23554941; PMCID: PMC3595211.
14. Adams et al., 2004. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res. 2004 Aug 1;64(15):5471-80. doi: 10.1158/0008-5472.CAN-04-0447. PMID: 15289357.
15. Levandowski et al., 2013. NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1β processing via the NLRP1 inflammasome. Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2952-6. doi: 10.1073/pnas.1222808110. Epub 2013 Feb 4. PMID: 23382179; PMCID: PMC3581876.